Search

Your search keyword '"Nedovic, D."' showing total 14 results
Start Over Author "Nedovic, D." Search Limiters Full Text
14 results on '"Nedovic, D."'

1. The management of multiple sclerosis by reference centers in Italy: health demands and needs in Campania region

Author

de Waure, C., Di Nardo, F., Mazzucco, W., Nedovic, D., Ricciardi, W, Battaglia, MA, Busillo, V, Di Iorio, W, Gallo, A, Lanzillo, R, Lombardi, E, Maniscalco, G, Orefice, G, Petracca, M, Romano, F, Sinisi, L, Spadera, A, Spitaleri, D, Vivo, P, de Waure, C., Di Nardo, F., Mazzucco, W., Nedovic, D., Ricciardi, W, Battaglia, MA, Busillo, V, Di Iorio, W, Gallo, A, Lanzillo, R, Lombardi, E, Maniscalco, G, Orefice, G, Petracca, M, Romano, F, Sinisi, L, Spadera, A, Spitaleri, D, and Vivo, P

Subjects
multiple sclerosi, epidemiology, Settore MED/42 - Igiene Generale E Applicata, management
Abstract

This cross-sectional study has investigated the diagnostic and therapeutic management of patients suffering from multiple sclerosis (MS) in the Campania Region (Italy). A survey involving all the reference centers for MS in Campania Region was conducted from March to August 2011. Centers responded to a web-administered questionnaire on management and clinical characteristics of MS patients. In the study period, 3263 patients (mean age 37 years, 66 % females) accessed the centers. Patients received a first diagnosis of MS in 161 cases (4.9 %). About 37 % of the subjects without a previous diagnosis came to the centers on their own initiative. All patients underwent a complete neurological examination and expanded disability status scale. The other most common investigations were magnetic resonance imaging (44.0 %) and evoked potentials (22.1 %). The number of treated patients was 2797 (87.1 %). The most used drugs were interferon b and glatiramer acetate. The time between diagnosis and initiation of therapy exceeded 6 months in 32 % of cases. Second-line drugs were under-used: 16 % of patients who might benefit from them show high clinical and radiological disease activity despite treatment with immunomodulant drugs. The MS care management of the surveyed centers showed consistent margins for improvement in 2011. Even though these data do not represent the current situation, they can be used to monitor improvements in MS care.

Published
2015

4. The management of multiple sclerosis by reference centers in south of Italy: a 2011 survey on health demands and needs in Campania region

Author

DE WAURE, CHIARA, DI NARDO, FRANCESCO, MAZZUCCO, WALTER, NEDOVIC, D, BATTAGLIA, MA, BUSILLO, V, DI IORIO, W, GALLO, A, LANZILLO, R, LOMBARDI, E, MANISCALCO, GT, OREFICE, G, PETRACCA, M, ROMANO, F, SINISI, L, SPADERA, AP, SPITALERI, D, VIVO, P, RICCIARDI, GUALTIERO, DE WAURE, CHIARA, DI NARDO, FRANCESCO, MAZZUCCO, WALTER, NEDOVIC, D, BATTAGLIA, MA, BUSILLO, V, DI IORIO, W, GALLO, A, LANZILLO, R, LOMBARDI, E, MANISCALCO, GT, OREFICE, G, PETRACCA, M, ROMANO, F, SINISI, L, SPADERA, AP, SPITALERI, D, VIVO, P, and RICCIARDI, GUALTIERO

Published
2015

7. Carotenoid Intake from Natural Sources and Head and Neck Cancer: A Systematic Review and Meta-analysis of Epidemiological Studies

Author

Leoncini, Emanuele, Nedovic, D, Panic, N, Pastorino, Roberta, Edefonti, V, Boccia, Stefania, Pastorino, Roberta (ORCID:0000-0001-5013-0733), Boccia, Stefania (ORCID:0000-0002-1864-749X), Leoncini, Emanuele, Nedovic, D, Panic, N, Pastorino, Roberta, Edefonti, V, Boccia, Stefania, Pastorino, Roberta (ORCID:0000-0001-5013-0733), and Boccia, Stefania (ORCID:0000-0002-1864-749X)

Abstract

This meta-analysis aimed to compare the efficacy and adverse events, either serious or mild/moderate, of all generic versus brand-name cardiovascular medicines. We searched randomized trials in MEDLINE, Scopus, EMBASE, Cochrane Controlled Clinical Trial Register, and ClinicalTrials.gov (last update December 1, 2014). Attempts were made to contact the investigators of all potentially eligible trials. Two investigators independently extracted and analyzed soft (including systolic blood pressure, LDL cholesterol, and others) and hard efficacy outcomes (including major cardiovascular adverse events and death), minor/moderate and serious adverse events. We included 74 randomized trials; 53 reported ≥1 efficacy outcome (overall sample 3051), 32 measured mild/moderate adverse events (n = 2407), and 51 evaluated serious adverse events (n = 2892). We included trials assessing ACE inhibitors (n = 12), anticoagulants (n = 5), antiplatelet agents (n = 17), beta-blockers (n = 11), calcium channel blockers (n = 7); diuretics (n = 13); statins (n = 6); and others (n = 3). For both soft and hard efficacy outcomes, 100 % of the trials showed non-significant differences between generic and brand-name drugs. The aggregate effect size was 0.01 (95 % CI -0.05; 0.08) for soft outcomes; -0.06 (-0.71; 0.59) for hard outcomes. All but two trials showed non-significant differences in mild/moderate adverse events, and aggregate effect size was 0.07 (-0.06; 0.20). Comparable results were observed for each drug class and in each stratified meta-analysis. Overall, 8 serious possibly drug-related adverse events were reported: 5/2074 subjects on generics; 3/2076 subjects on brand-name drugs (OR 1.69; 95 % CI 0.40-7.20). This meta-analysis strengthens the evidence for clinical equivalence between brand-name and generic cardiovascular drugs. Physicians could be reassured about prescribing generic cardiovascular drugs, and health care organization about endorsing their wider use.

Published
2015

11. The management of multiple sclerosis by reference centers in south of Italy: a 2011 survey on health demands and needs in Campania region

Author

Daniele Spitaleri, Emilio Lombardi, Walter Di Iorio, Roberta Lanzillo, Mario Alberto Battaglia, Anna Pia Spadera, F. Romano, Giuseppe Orefice, Antonio Gallo, Pasquale Vivo, Francesco Di Nardo, Darko Nedovic, Vincenzo Busillo, Giorgia Teresa Maniscalco, Chiara De Waure, Walter Mazzucco, Walter Ricciardi, Leonardo Sinisi, Maria Petracca, de Waure, Chiara, Di Nardo, Francesco, Mazzucco, Walter, Nedovic, Darko, Battaglia, Mario Alberto, Busillo, Vincenzo, Di Iorio, Walter, Gallo, Antonio, Lanzillo, Roberta, Lombardi, Emilio, Maniscalco, Giorgia Teresa, Orefice, Giuseppe, Petracca, Maria, Romano, Felice, Sinisi, Leonardo, Spadera, Anna Pia, Spitaleri, Daniele, Vivo, Pasquale, Ricciardi, Walter, de Waure, C, Di Nardo, F, Mazzucco, W, Nedovic, D, Battaglia, Ma, Busillo, V, Di Iorio, W, Lanzillo, R, Lombardi, E, Maniscalco, Gt, Orefice, G, Petracca, M, Romano, F, Sinisi, L, Spadera, Ap, Spitaleri, D, Vivo, P, and Ricciardi, W.

Subjects
Adult, Male, medicine.medical_specialty, Pediatrics, Multiple Sclerosis, Cross-sectional study, Neurological examination, Dermatology, Disease management, Health services needs and demand, Multiple sclerosis, Cross-Sectional Studies, Female, Humans, Italy, Surveys and Questionnaires, Needs Assessment, 2708, Neurology (clinical), Psychiatry and Mental Health, 03 medical and health sciences, 0302 clinical medicine, medicine, Multiple sclerosi, 030212 general & internal medicine, Disease management (health), Glatiramer acetate, Settore MED/42 - IGIENE GENERALE E APPLICATA, Neuroradiology, Expanded Disability Status Scale, medicine.diagnostic_test, business.industry, General Medicine, Management of multiple sclerosis, medicine.disease, Psychiatry and Mental health, Physical therapy, business, 030217 neurology & neurosurgery, medicine.drug
Abstract

This cross-sectional study has investigated the diagnostic and therapeutic management of patients suffering from multiple sclerosis (MS) in the Campania Region (Italy). A survey involving all the reference centers for MS in Campania Region was conducted from March to August 2011. Centers responded to a web-administered questionnaire on management and clinical characteristics of MS patients. In the study period, 3263 patients (mean age 37 years, 66 % females) accessed the centers. Patients received a first diagnosis of MS in 161 cases (4.9 %). About 37 % of the subjects without a previous diagnosis came to the centers on their own initiative. All patients underwent a complete neurological examination and expanded disability status scale. The other most common investigations were magnetic resonance imaging (44.0 %) and evoked potentials (22.1 %). The number of treated patients was 2797 (87.1 %). The most used drugs were interferon β and glatiramer acetate. The time between diagnosis and initiation of therapy exceeded 6 months in 32 % of cases. Second-line drugs were under-used: 16 % of patients who might benefit from them show high clinical and radiological disease activity despite treatment with immunomodulant drugs. The MS care management of the surveyed centers showed consistent margins for improvement in 2011. Even though these data do not represent the current situation, they can be used to monitor improvements in MS care.

Published
2015

12. Evaluation of the Endorsement of the STrengthening the REporting of Genetic Association Studies (STREGA) Statement on the Reporting Quality of Published Genetic Association Studies.

Author

Nedovic D, Panic N, Pastorino R, Ricciardi W, and Boccia S

Subjects
Humans, Genetic Association Studies, Periodicals as Topic standards, Publishing standards, Research Report standards
Abstract

The STrengthening the REporting of Genetic Association studies (STREGA) statement was based on the STrengthening the REporting of OBservational studies in Epidemiology (STROBE) statement, and it was published in 2009 in order to improve the reporting of genetic association (GA) studies. Our aim was to evaluate the impact of STREGA endorsement on the quality of reporting of GA studies published in journals in the field of genetics and heredity (GH). Quality of reporting was evaluated by assessing the adherence of papers to the STREGA checklist. After identifying the GH journals that endorsed STREGA in their instructions for authors, we randomly appraised papers published in 2013 from journals endorsing STREGA that published GA studies (Group A); in GH journals that never endorsed STREGA (Group B); in GH journals endorsing STREGA, but in the year preceding its endorsement (Group C); and in the same time period as Group C from GH journals that never endorsed STREGA (Group D). The STREGA statement was referenced in 29 (18.1%) of 160 GH journals, of which 18 (62.1%) journals published GA studies. Among the 18 journals endorsing STREGA, we found a significant increase in the overall adherence to the STREGA checklist over time (A vs C; P < 0.0001). Adherence to the STREGA checklist was significantly higher in journals endorsing STREGA compared to those that did not endorse the statement (A vs B; P = 0.04). No significant improvement was detected in the adherence to STREGA items in journals not endorsing STREGA over time (B vs D; P > 0.05). The endorsement of STREGA resulted in an increase in quality of reporting of GA studies over time, while no similar improvement was reported for journals that never endorsed STREGA.

Published
2016
Full Text
View/download PDF

13. Reduction in Neisseria meningitidis infection in Italy after Meningococcal C conjugate vaccine introduction: A time trend analysis of 1994-2012 series.

Author

de Waure C, Miglietta A, Nedovic D, Mereu G, and Ricciardi W

Subjects
Adolescent, Adult, Aged, Child, Child, Preschool, Humans, Immunization Programs, Infant, Italy epidemiology, Meningococcal Infections immunology, Meningococcal Infections microbiology, Middle Aged, Serogroup, Vaccination, Young Adult, Meningococcal Infections epidemiology, Meningococcal Vaccines immunology, Neisseria meningitidis immunology, Vaccines, Conjugate immunology
Abstract

The incidence of invasive meningococcal disease (IMD) in Italy is among the lowest in Europe. Meningococcal C conjugate vaccine (MCC) was introduced in 2005 for 12 months old infants. The aim of this study was to describe the epidemiology of IMD in Italy from 1994 to 2012 and to evaluate the impact of MCC introduction. Data about Neisseria meningitidis (N. meningitidis) cases were drawn from the National Surveillance of Invasive Bacterial Diseases. The average incidence of IMD during 1994-2012 in Italy was 0.36 per 100,000 (95%CI 0.30; 0.40). N. meningitidis B was the most frequent serogroup and infants less than 12 months old were the most affected. Joinpoint analysis showed a statistically significant reduction in the incidence of N. meningitidis C related IMD after MCC introduction: the Annual Percentage Change declined from 21.8 (95%CI 15.1; 28.9) in 1994-2005 to -19.9 (95%CI -28.2; -10.7) afterwards. No changes were observed with respect to N. meningitidis B related IMD. Poisson regression showed a statistically significant reduction in the incidence of IMD both associated to N. meningitidis C (Incidence Rate Ratio 0.33; 95%CI 0.29; 0.37) and due to all serogroups (Incidence Rate Ratio 0.70; 95%CI 0.65; 0.75) in the post-vaccination period compared to the pre-vaccination one. On the other hand, the incidence of N. meningitidis B related IMD did not decrease. Our results suggest that MCC had an impact in decreasing the incidence of N. meningitidis C related IMD. However, data on typing are incomplete and efforts are needed to make them available for studying the need and the impact of other meningococcal vaccines.

Published
2016
Full Text
View/download PDF

14. Carotenoid Intake from Natural Sources and Head and Neck Cancer: A Systematic Review and Meta-analysis of Epidemiological Studies.

Author

Leoncini E, Nedovic D, Panic N, Pastorino R, Edefonti V, and Boccia S

Subjects
Antioxidants therapeutic use, Epidemiologic Studies, Global Health, Head and Neck Neoplasms epidemiology, Humans, Morbidity trends, Risk Factors, Carotenoids therapeutic use, Dietary Supplements, Head and Neck Neoplasms prevention & control
Abstract

Because of their role as antioxidants, the intake of carotenoids has been hypothesized to reduce the risk of head and neck cancer (HNC). We conducted a systematic review and meta-analysis of the epidemiological studies to investigate whether the intake of specific carotenoids from dietary sources, as well as combined carotenoids, is associated with the risk of HNC according to cancer subsites. A comprehensive literature search of the Medline and Scopus databases was conducted. Sixteen articles were identified from the literature search, of which 15 were case-control studies and one prospective cohort study. The risk reduction associated with β-carotene equivalents intake was 46% (95% CI, 20%-63%) for cancer of oral cavity and 57% (95% CI, 23%-76%) for laryngeal cancer. Lycopene and β-cryptoxanthin also reduced the risk for laryngeal cancer; the ORs for the highest category compared with the lowest one of carotenoid intake were 50% (95% CI, 11%-72%) and 59% (95% CI, 49%-67%), respectively. Lycopene, α-carotene, and β-cryptoxanthin were associated with at least 26% reduction in the rate of oral and pharyngeal cancer (95% CI, 2%-44%). Our systematic review and meta-analysis on dietary carotenoids intake and HNC showed carotenoids to act protectively against HNC, in relation to most of single nutrients and subsites., (©2015 American Association for Cancer Research.)

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results